Call: 0207 309 2222
Call: 0207 309 2222
Jeffreys Henry LLP advise Open Orphan Plc on £13 million all-share merger with hVIVO Plc
The enlarged group was re-admitted to AIM and Euronext Growth on 20th January 2020 and completed a placing of £5.3 million on 31 January 2020.
Open Orphan Plc are building a leading European specialist pharmaceutical services company which includes a focus on orphan drug services by acquiring and consolidating a series of European services companies.
hVIVO Plc is an industry leading services provider in the viral challenge studies and virology laboratory services. It has developed a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases.
It is hoped the merger will result in synergies across the Enlarged Group with each business providing complementary services with limited overlap in existing capabilities and customers.
Jeffreys Henry LLP acted as the Reporting Accountant in respect of the merger and subsequent re-admission.
This latest announcement further strengthens Jeffreys Henry LLP’s credentials within the AIM market.
Earlier this year, Jeffreys Henry LLP rose to 10th place in the latest league table of Auditors ranked by Total of Stock Market clients.
With a total of 27* UK listed clients, a dedicated capital markets team and shorter reporting lines, Jeffreys Henry LLP is able to offer a cost-effective AIM audit service for companies already listed, or considering listing, on the London Stock Exchange, AIM, NEX and other European markets.
*As of January 2020
REVIEW YOUR AIM AUDIT FEE
For further information, or to review your current audit fee,
please contact Nick Michaels
or Sanjay Parmar
on 0207 309 2222.
